|
1
|
Fukuoka M, Yano S, Giaccone G, et al:
Multi-institutional randomized phase II trial of gefitinib for
previously treated patients with advanced non-small-cell lung
cancer (The IDEAL 1 Trial) (corrected). J Clin Oncol. 21:2237–2246.
2003.Erratum in: J Clin Oncol 22: 4863, 2004.
|
|
2
|
Lynch TJ, Adjei AA, Bunn PA Jr, et al:
Summary statement: novel agents in the treatment of lung cancer:
advances in epidermal growth factor receptor-targeted agents. Clin
Cancer Res. 12:4365s–4371s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perez-Soler R, Chachoua A, Hammond LA, et
al: Determinants of tumor response and survival with erlotinib in
patients with non-small-cell lung cancer. J Clin Oncol.
22:3238–3247. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Laskin JJ and Sandler AB: Epidermal growth
factor receptor: a promising target in solid tumours. Cancer Treat
Rev. 30:1–17. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): an open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
7
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jackman D, Pao W, Riely GJ, et al:
Clinical definition of acquired resistance to epidermal growth
factor receptor tyrosine kinase inhibitors in non-small-cell lung
cancer. J Clin Oncol. 28:357–360. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pao W, Wang TY, Riely GJ, et al: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi S, Boggon TJ, Dayaram T, et al:
EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pao W, Miller VA, Politi KA, et al:
Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase
domain. PLoS Med. 2:e732005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li D, Shimamura T, Ji H, et al: Bronchial
and peripheral murine lung carcinomas induced by T790M-L858R mutant
EGFR respond to HKI-272 and rapamycin combination therapy. Cancer
Cell. 12:81–93. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou W, Ercan D, Chen L, et al: Novel
mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature.
462:1070–1074. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
da Rocha Dias S, Friedlos F, Light Y,
Springer C, Workman P and Marais R: Activated B-RAF is an Hsp90
client protein that is targeted by the anticancer drug
17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65:10686–10691.
2005.PubMed/NCBI
|
|
17
|
Shimamura T, Lowell AM, Engelman JA and
Shapiro GI: Epidermal growth factor receptors harboring kinase
domain mutations associate with the heat shock protein 90 chaperone
and are destabilized following exposure to geldanamycins. Cancer
Res. 65:6401–6408. 2005. View Article : Google Scholar
|
|
18
|
Webb CP, Hose CD, Koochekpour S, et al:
The geldanamycins are potent inhibitors of the hepatocyte growth
factor/scatter factor-met-urokinase plasminogen activator-plasmin
proteolytic network. Cancer Res. 60:342–349. 2000.PubMed/NCBI
|
|
19
|
Yang S, Qu S, Perez-Tores M, et al:
Association with HSP90 inhibits Cbl-mediated down-regulation of
mutant epidermal growth factor receptors. Cancer Res. 66:6990–6997.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pratilas CA, Hanrahan AJ, Halilovic E, et
al: Genetic predictors of MEK dependence in non-small cell lung
cancer. Cancer Res. 68:9375–9383. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shimamura T, Li D, Ji H, et al: Hsp90
inhibition suppresses mutant EGFR-T790M signaling and overcomes
kinase inhibitor resistance. Cancer Res. 68:5827–5838. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sausville EA, Tomaszewski JE and Ivy P:
Clinical development of 17-allylamino, 17-demethoxygeldanamycin.
Curr Cancer Drug Targets. 3:377–383. 2003. View Article : Google Scholar
|
|
23
|
Supko JG, Hickman RL, Grever MR and
Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as
an antitumor agent. Cancer Chemother Pharmacol. 36:305–315. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kim W, Lee D, Hong SS, et al: Rational
biosynthetic engineering for optimization of geldanamycin
analogues. Chembiochem. 10:1243–1251. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim W, Lee JS, Lee D, et al: Mutasynthesis
of geldanamycin by the disruption of a gene producing starter unit:
generation of structural diversity at the benzoquinone ring.
Chembiochem. 8:1491–1494. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
27
|
Koga F, Kihara K and Neckers L: Inhibition
of cancer invasion and metastasis by targeting the molecular
chaperone heat-shock protein 90. Anticancer Res. 29:797–807.
2009.PubMed/NCBI
|
|
28
|
Whitesell L and Lindquist SL: HSP90 and
the chaperoning of cancer. Nat Rev Cancer. 5:761–772. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jolly C and Morimoto RI: Role of the heat
shock response and molecular chaperones in oncogenesis and cell
death. J Natl Cancer Inst. 92:1564–1572. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Workman P: Altered states: selectively
drugging the Hsp90 cancer chaperone. Trends Mol Med. 10:47–51.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gallegos Ruiz MI, Floor K, Roepman P, et
al: Integration of gene dosage and gene expression in non-small
cell lung cancer, identification of HSP90 as potential target. PloS
One. 3:e00017222008.PubMed/NCBI
|
|
32
|
Engelman JA, Janne PA, Mermel C, et al:
ErbB-3 mediates phosphoinositide 3-kinase activity in
gefitinib-sensitive non-small cell lung cancer cell lines. Proc
Natl Acad Sci USA. 102:3788–3793. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shimamura T and Shapiro GI: Heat shock
protein 90 inhibition in lung cancer. J Thorac Oncol. 3:S152–S159.
2008. View Article : Google Scholar : PubMed/NCBI
|
